Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Alnylam Pharmaceuticals, Inc. keeps $13 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 25 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Alnylam Pharmaceuticals trailed consensus on both EPS and revenue in the second fiscal quarter of 2026, reported July 30, even as revenue surged year over year. Revenue rose 66.9% to about $1.3 billion (up from roughly $773.7 million a year ago), but revenue of $1.291 billion trailed the $1.322 billion estimate (-2.4%). EPS of $1.21 trailed the $1.63 estimate (-25.8%), improving from -$0.51 a year ago, while net income turned positive to about $164.5 million versus a loss of roughly $66.3 million a year earlier. Profitability tracked with a gross margin near 77% and operating margin around 18%, alongside gross profit of about $992.7 million and operating income of roughly $231.4 million. The company generated operating cash flow of about $75.3 million. Next-period consensus calls for EPS of $2.19 on revenue of $1.429 billion.
Next report — what to expect
Alnylam Pharmaceuticals, Inc. (ALNY) reports next on October 29, 2026. The Street is looking for EPS of $1.77 on revenue of $1.43 billion. As trailing context, revenue rose +66.9% year over year last quarter. ALNY has beaten EPS in 5 of 8 most recent quarters.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. develops RNA interference medicines in biotechnology and markets treatments for rare diseases, with $3.7 billion in revenue in FY2025. Listed on NASDAQ as ALNY, the company sells ONPATTRO for polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1.
Today's Snapshot
The day ended with ALNY 5% lower at 219.72, while its sector was flat. Volume was about a quarter more than its usual level.
Trading Volume
Above 10d avg 1.2M
1.6M
vs S&P 500 Today
Strong Underperformance
-5.74%
Updated: October 2, 2026 at 20:11 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$241.66 - $310.86Sell
- RSI (14)34.34Neutral
- Stochastic %K (14, 3, 3)18.48Buy
- MACD Level (12, 26)-2.41Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.